Torrent Pharmaceuticals
Torrent Pharmaceuticals Limited, commonly known as Torrent Pharma, is a prominent player in the global pharmaceutical industry, headquartered in Ahmedabad, India. Founded in 1959, the company has established a strong presence in various operational regions, including North America, Europe, and emerging markets across Asia and Africa. Specialising in the development, manufacturing, and marketing of a diverse range of generic and branded pharmaceuticals, Torrent Pharma focuses on therapeutic areas such as cardiovascular, central nervous system, and anti-infectives. The company is recognised for its commitment to quality and innovation, which has led to significant milestones, including a robust portfolio of over 200 products. With a strong market position, Torrent Pharmaceuticals has garnered accolades for its research and development capabilities, making it a trusted name in the industry. Its dedication to improving patient outcomes through affordable healthcare solutions sets it apart in a competitive landscape.
DitchCarbon Score
How does Torrent Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Torrent Pharmaceuticals's score of 29 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Torrent Pharmaceuticals's reported carbon emissions
In 2025, Torrent Pharmaceuticals reported significant carbon emissions, with Scope 1 emissions at approximately 8,937,000 kg CO2e, Scope 2 emissions at about 78,592,000 kg CO2e, and Scope 3 emissions reaching approximately 154,837,270 kg CO2e. The Scope 3 emissions breakdown includes capital goods (984,200 kg CO2e), business travel (23,182,710 kg CO2e), employee commute (5,150,730 kg CO2e), and purchased goods and services (67,010,170 kg CO2e). The company has disclosed emissions data for Scopes 1, 2, and 3, indicating a comprehensive approach to tracking its carbon footprint. However, there are currently no specific reduction targets or climate pledges outlined in their reports. The emissions data is cascaded from Torrent Pharmaceuticals Limited, reflecting their commitment to transparency in environmental reporting. In previous years, emissions were also substantial, with 2024 figures showing Scope 1 emissions at approximately 15,294,000 kg CO2e and Scope 2 emissions at about 76,268,000 kg CO2e. In 2023, the company reported Scope 1 emissions of around 25,063,000 kg CO2e and Scope 2 emissions of approximately 97,111,000 kg CO2e. Overall, while Torrent Pharmaceuticals has made strides in emissions reporting, the absence of defined reduction targets suggests an opportunity for further commitment to climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 28,072,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 96,026,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Torrent Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
